Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

IKKα kinase regulates the DNA damage response and drives chemo-resistance in cancer

  • Colomer Montañà, Carlota, 1990-
  • Margalef González, Pol, 1985-
  • Villanueva, Alberto
  • Vert, Anna
  • Pecharroman, Irene
  • Solé, Laura
  • González-Farré, Mónica
  • Alonso, Josune
  • Montagut Viladot, Clara
  • Martínez Iniesta, María
  • Bertran, Joan
  • Borràs, Eva
  • Iglesias Coma, Mar
  • Sabidó Aguadé, Eduard, 1981-
  • Bigas Salvans, Anna
  • Boulton, Simon J.
  • Espinosa Blay, Lluís
Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling. Insights into the sources of IKKα(p45) activation and its downstream substrates in the nucleus remain to be defined. Here, we discover that IKKα(p45) is rapidly activated by DNA damage independent of ATM-ATR, but dependent on BRAF-TAK1-p38-MAPK, and is required for robust ATM activation and efficient DNA repair. Abolishing BRAF or IKKα activity attenuates ATM, Chk1, MDC1, Kap1, and 53BP1 phosphorylation, compromises 53BP1 and RIF1 co-recruitment to sites of DNA lesions, and inhibits 53BP1-dependent fusion of dysfunctional telomeres. Furthermore, IKKα or BRAF inhibition synergistically enhances the therapeutic potential of 5-FU and irinotecan to eradicate chemotherapy-resistant metastatic human tumors in vivo. Our results implicate BRAF and IKKα kinases in the DDR and reveal a combination strategy for cancer treatment., This work was funded by grants from Instituto de Salud Carlos III FEDER (PIE15/00008 and PI16/00437), Generalitat de Catalunya 2017SGR135, and the “Xarxa de Bancs de Tumors” sponsored by Pla Director d’Oncologia de Catalunya (XBTC). C.C. is supported by FPI BES-2014-068451 and the EMBO Short-Term Fellowship (na7084). P.M. is supported by funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement #702430. The Boulton lab is supported by The Francis Crick Institute, which receives its core funding from Cancer Research UK (FC0010048), the UK Medical Research Council (FC0010048), and the Wellcome Trust (FC0010048). S.J.B. is funded by European Research Council (ERC) Advanced Investigator Grants (TelMetab) and a Wellcome Trust Senior Investigator Grant. The Centre de Regulació Genòmica/Universitat Pompeu Fabra Proteomics Unit is part of the “Plataforma de Recursos Biomoleculares y Bioinformáticos (ProteoRed)” supported by grant PT13/0001 of Instituto de Salud Carlos III from the Spanish government and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2014SGR678). We acknowledge support from the Spanish Ministry of Economy and Competitiveness and “Centro de Excelencia Severo Ochoa 2013-2017” (SEV-2012-0208).
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer

  • Colomer, Carlota
  • Margalef, Pol
  • Villanueva Garatachea, Alberto
  • Vert, Anna
  • Pecharroman, Irene
  • Sole, Laura
  • González Farré, Mónica
  • Alonso, Josune
  • Montagut Viladot, Clara
  • Martínez Iniesta, María
  • Bertran, Joan
  • Borràs, Eva
  • Iglesias, Mar
  • Sabidó Aguadé, Eduard
  • Bigas Salvans, Anna
  • Boulton, Simon J.
  • Espinosa, Lluís
Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling. Insights into the sources of IKKα(p45) activation and its downstream substrates in the nucleus remain to be defined. Here, we discover that IKKα(p45) is rapidly activated by DNA damage independent of ATM-ATR, but dependent on BRAF-TAK1-p38-MAPK, and is required for robust ATM activation and efficient DNA repair. Abolishing BRAF or IKKα activity attenuates ATM, Chk1, MDC1, Kap1, and 53BP1 phosphorylation, compromises 53BP1 and RIF1 co-recruitment to sites of DNA lesions, and inhibits 53BP1-dependent fusion of dysfunctional telomeres. Furthermore, IKKα or BRAF inhibition synergistically enhances the therapeutic potential of 5-FU and irinotecan to eradicate chemotherapy-resistant metastatic human tumors in vivo. Our results implicate BRAF and IKKα kinases in the DDR and reveal a combination strategy for cancer treatment.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer

  • Colomer, Carlota
  • Margalef, Pol
  • Villanueva Garatachea, Alberto
  • Vert, Anna
  • Pecharroman, Irene
  • Sole, Laura
  • González Farré, Mónica
  • Alonso, Josune
  • Montagut Viladot, Clara
  • Martínez Iniesta, María
  • Bertran, Joan
  • Borràs, Eva
  • Iglesias, Mar
  • Sabidó Aguadé, Eduard
  • Bigas Salvans, Anna
  • Boulton, Simon J.
  • Espinosa, Lluís
Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling. Insights into the sources of IKKα(p45) activation and its downstream substrates in the nucleus remain to be defined. Here, we discover that IKKα(p45) is rapidly activated by DNA damage independent of ATM-ATR, but dependent on BRAF-TAK1-p38-MAPK, and is required for robust ATM activation and efficient DNA repair. Abolishing BRAF or IKKα activity attenuates ATM, Chk1, MDC1, Kap1, and 53BP1 phosphorylation, compromises 53BP1 and RIF1 co-recruitment to sites of DNA lesions, and inhibits 53BP1-dependent fusion of dysfunctional telomeres. Furthermore, IKKα or BRAF inhibition synergistically enhances the therapeutic potential of 5-FU and irinotecan to eradicate chemotherapy-resistant metastatic human tumors in vivo. Our results implicate BRAF and IKKα kinases in the DDR and reveal a combination strategy for cancer treatment.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

IKKα kinase regulates the DNA damage response and drives chemo-resistance in cancer

  • Colomer Montañà, Carlota, 1990-
  • Margalef González, Pol, 1985-
  • Villanueva, Alberto
  • Vert, Anna
  • Pecharroman, Irene
  • Solé, Laura
  • González-Farré, Mónica
  • Alonso, Josune
  • Montagut Viladot, Clara
  • Martínez Iniesta, María
  • Bertran, Joan
  • Borràs, Eva
  • Iglesias Coma, Mar
  • Sabidó Aguadé, Eduard, 1981-
  • Bigas Salvans, Anna
  • Boulton, Simon J.
  • Espinosa Blay, Lluís
Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling. Insights into the sources of IKKα(p45) activation and its downstream substrates in the nucleus remain to be defined. Here, we discover that IKKα(p45) is rapidly activated by DNA damage independent of ATM-ATR, but dependent on BRAF-TAK1-p38-MAPK, and is required for robust ATM activation and efficient DNA repair. Abolishing BRAF or IKKα activity attenuates ATM, Chk1, MDC1, Kap1, and 53BP1 phosphorylation, compromises 53BP1 and RIF1 co-recruitment to sites of DNA lesions, and inhibits 53BP1-dependent fusion of dysfunctional telomeres. Furthermore, IKKα or BRAF inhibition synergistically enhances the therapeutic potential of 5-FU and irinotecan to eradicate chemotherapy-resistant metastatic human tumors in vivo. Our results implicate BRAF and IKKα kinases in the DDR and reveal a combination strategy for cancer treatment., This work was funded by grants from Instituto de Salud Carlos III FEDER (PIE15/00008 and PI16/00437), Generalitat de Catalunya 2017SGR135, and the “Xarxa de Bancs de Tumors” sponsored by Pla Director d’Oncologia de Catalunya (XBTC). C.C. is supported by FPI BES-2014-068451 and the EMBO Short-Term Fellowship (na7084). P.M. is supported by funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement #702430. The Boulton lab is supported by The Francis Crick Institute, which receives its core funding from Cancer Research UK (FC0010048), the UK Medical Research Council (FC0010048), and the Wellcome Trust (FC0010048). S.J.B. is funded by European Research Council (ERC) Advanced Investigator Grants (TelMetab) and a Wellcome Trust Senior Investigator Grant. The Centre de Regulació Genòmica/Universitat Pompeu Fabra Proteomics Unit is part of the “Plataforma de Recursos Biomoleculares y Bioinformáticos (ProteoRed)” supported by grant PT13/0001 of Instituto de Salud Carlos III from the Spanish government and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2014SGR678). We acknowledge support from the Spanish Ministry of Economy and Competitiveness and “Centro de Excelencia Severo Ochoa 2013-2017” (SEV-2012-0208).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer

  • Colomer, Carlota
  • Margalef, Pol
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Vert, Anna
  • Pecharroman, Irene
  • Solé Font, Laura|||0000-0002-3195-0565
  • Gonzàlez-Farré, Mònica|||0000-0002-0653-0980
  • Alonso, Josune|||0000-0001-6783-5166
  • Montagut, Clara
  • Martinez-Iniesta, Maria
  • Bertran, Joan
  • Borràs, Eva|||0000-0002-3859-9907
  • Iglesias, Mar|||0000-0002-2274-4671
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Boulton, Simon J.
  • Espinosa, Lluis|||0000-0002-2897-4099
Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling. Insights into the sources of IKKα(p45) activation and its downstream substrates in the nucleus remain to be defined. Here, we discover that IKKα(p45) is rapidly activated by DNA damage independent of ATM-ATR, but dependent on BRAF-TAK1-p38-MAPK, and is required for robust ATM activation and efficient DNA repair. Abolishing BRAF or IKKα activity attenuates ATM, Chk1, MDC1, Kap1, and 53BP1 phosphorylation, compromises 53BP1 and RIF1 co-recruitment to sites of DNA lesions, and inhibits 53BP1-dependent fusion of dysfunctional telomeres. Furthermore, IKKα or BRAF inhibition synergistically enhances the therapeutic potential of 5-FU and irinotecan to eradicate chemotherapy-resistant metastatic human tumors in vivo. Our results implicate BRAF and IKKα kinases in the DDR and reveal a combination strategy for cancer treatment. Colomer et al. discover that IKKα kinase contributes to the chemo- and radio-resistance of cancer cells by facilitating ATM activation and DNA repair. BRAF inhibitors prevent damage-induced IKKα activation, leading to the attenuation of ATM signaling and DNA repair. IKKα depletion or BRAF inhibitors combined with 5-FU and irinotecan synergistically enhance the killing of patient-derived xenograft tumors.